These effects may be related, as inhibition of Topo1 has been shown to lead to RNA polymerase II and DNA polymerase stalling [50], and treatment of prostate cancer cells with topoisomerase inhibitors has been shown to attenuate AR signaling [35, 36, 51, 52]. Here, AR is linked to prostate carcinoma.